Clinical trial
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in…
NCT00454480 · The University of New South Wales, Other · Completed
Key facts
| NCT number | NCT00454480 |
|---|---|
| Title | Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes |
| Official title | A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome |
| Lead sponsor | The University of New South Wales, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Biological, Drug, Genetic, Other, Procedure |
| Interventions | alemtuzumab, arsenic trioxide, azacitidine, busulfan, clofarabine, cytarabine, daunorubicin hydrochloride, fludarabine phosphate, gemtuzumab ozogamicin, melphalan and 9 more |
| Enrollment | 2,000 |
| Start date | Aug 1, 2006 |
| Primary completion | Aug 1, 2012 |
| First posted | Mar 30, 2007 |
| Last update posted | Aug 26, 2013 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: